Tesla owners with 200,000 to 554,000 miles reveal the charging habits that kept their original batteries alive, and one ...

Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite ...

High rate of tumor DNA clearance with chemoimmunotherapy portends improved EFS, possibly O ...

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne(R) CDx as a ...

Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus ...

A deep learning platform may help predict how people with advanced lung cancer will respond to immunotherapy, according to ...

Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...

Bristol-Myers Squibb (NYSE:BMY | BMY Price Prediction) trades at $60.17 as of writing. The 24/7 Wall St. Price Target is ...

The team coordinated multiple design disciplines, authority approvals and specialist sub-consultants, with a clear focus on ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from ...